Author

W. J. Huang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:proteomics· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

J. Zhang· 3 shared X. Zheng· 3 shared F. J. Shen· 2 shared G. Z. Wu· 2 shared J. G. Su· 2 shared J. J. Wu· 2 shared J. W. Hou· 2 shared L. F. Du· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

J. Zhang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus

Y. Zhang, M. Zhang, H. Wu, X. Wang, H. Zheng, J. Feng, J. Wang, L. Luo, H. Xiao, C. Qiao, X. Li, Y. Zheng, W. J. Huang, Y. Wang, Y. Wang, , G. Chen

This study identifies a novel human antibody, AF-03, that targets MARV glycoprotein and shows neutralizing activity against MARV and related filoviruses.

bioRxiv · Sep 17, 2023Immunology

Spike-specific CXCR3+ TFH cells play a dominant functional role in supporting antibody responses in SARS-CoV-2 infection and vaccination

J. Zhang, R. He, B. Liu, X. Zheng, Q. Wu, B. Wen, Q. Wang, Z. Liu, F. Chang, Y. Hu, T. Xie, Y. Liu, J. Chen, J. Yang, S. Teng, , X. Qu

This study identifies spike-specific CXCR3+ TFH cells as key drivers of long-term antibody responses in SARS-CoV-2 infection and vaccination.

bioRxiv · Aug 9, 2022 · PreprintImmunology

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants

J. Zhang, Z. B. Han, Y. Liang, X. F. Zhang, Y. Q. Jin, L. F. Du, S. Shao, H. Wang, J. W. Hou, K. Xu, Z. H. Lei, Z. M. Liu, J. Zhang, Y. N. Hou, N. Liu, , Q. M. Li

This study develops a mosaic-type trimeric RBD vaccine that induces strong neutralizing antibodies against Omicron and other SARS-CoV-2 variants in rats.

bioRxiv · Mar 29, 2022Immunology

Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2

Y. Liang, J. Zhang, R. Y. Yuan, M. Y. Wang, P. He, J. G. Su, Z. B. Han, Y. Q. Jin, J. W. Hou, H. Zhang, X. F. Zhang, S. Shao, Y. N. Hou, Z. M. Liu, L. F. Du, , Q. M. Li

This paper designs a trimeric RBD vaccine candidate with mutations from multiple SARS-CoV-2 strains, showing broad neutralization against variants including Beta and Kappa.

bioRxiv · Jun 18, 2021 · PreprintImmunology